Pretty amazing half yearly results for Clinuvel, slightly more...

Pretty amazing half yearly results for Clinuvel, slightly more than my forecast of more than 500% profit growth and in line with my expectations for full year results of a REVENUE EXPLOSION with more than 50 % full year growth in revenue and profits. This would give Clinuvel approximate full year earnings of $46 - 50 Million Revenue and $21 - $26 Million Profits depending on costs and we know CUV tightly control costs. These sort of amazing figures are broadly in line with Pro Medicus financials which has a market cap 5 times Clinuvel of about $5 Billion so plenty of upside to the current severe CUV undervaluation. An amazing fact for CUV is they could pay a special dividend right now of $1 per share and still leave a respectable amount in the bank (about $30 Million). So in future years I see this cash generating machine actually paying out very large dividends like CSL does now, obviously the share price will be much higher then but yields for early investors (eg current prices) will be enormous and this is why I never sell CSL regardless of enormous gains. Hopefully CUV can do something similar, on a smaller scale obviously, but with the US EPP market (the worlds biggest) just at the very start of producing incomes and more growth to come from Australia, Israel, Europe, Japan and the awesome market of China we can see growth to come for many years just on this 'proof of concept' rare disease.

This is the whole point of Clinuvel, if they can add ANY other indication to an already FDA, TGA, EMA and Israel approved and very safe drug they will become a $100 + share instantly. We know from the approval process that safety is the main thing looked at by regulators and we know Clinuvel has many years of data (including great safety record) from their drug. They have one of Australia's top neurosurgeons on the board and are targeting STROKE. Then there is Vitiligo which it can be seen from trial results will be almost cured in some skin types so FDA approval on trial structure is keenly awaited. Then there is the big one of DNA repair and SKIN CANCER treatment including the XP program. It will only take one. Management seem very confident as they have the knowledge of what the drug does, I'm backing them and can't wait for some readouts later this year. In the meantime I just have to be happy with watching awesome financial results roll in that very few companies can compare to in these tough times. Will be nice to see some analyst re-rates on this stock now that EPS has really shot up and hopefully some new analysts initiate coverage because it is pretty clear the share price will be much higher in 1 or 2 years than it is today.

All IMO DYOR